Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, ,Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
- Revenue in NZD (TTM)195.41m
- Net income in NZD15.61m
- Incorporated1997
- Employees110.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd | 96.33m | -2.70m | 250.00m | 944.00 | -- | -- | 83.94 | 2.60 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Lincoln Pharmaceuticals Ltd | 119.86m | 19.83m | 250.07m | 1.70k | 12.61 | -- | 11.31 | 2.09 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Bliss GVS Pharma Ltd | 161.95m | 12.84m | 251.53m | 831.00 | 19.86 | 1.23 | 12.48 | 1.55 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| AFT Pharmaceuticals Ltd | 195.41m | 15.61m | 260.07m | 110.00 | 16.66 | 2.96 | 14.76 | 1.33 | 0.1489 | 0.1489 | 1.86 | 0.8372 | 1.25 | 2.34 | 4.30 | 1,776,464.00 | 9.96 | 11.44 | 13.72 | 16.49 | 45.17 | 45.65 | 7.99 | 9.50 | 1.23 | 6.69 | 0.2683 | 4.43 | 24.75 | 18.08 | 46.51 | -- | 22.42 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 06 Nov 2024 | 7.52m | 7.17% |
| Guardians of New Zealand Superannuationas of 30 Apr 2024 | 1.70m | 1.62% |
| Salt Funds Management Ltd.as of 30 Apr 2024 | 319.83k | 0.31% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 73.45k | 0.07% |
| FCA Corp.as of 31 Aug 2024 | 46.00k | 0.04% |
